A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1982-03

AUTHORS

Joseph C. Allegra, Thomas M. Woodcock, Stephen P. Richman, Kirby I. Bland, James L. Wittliff

ABSTRACT

Complete remissions in patients with metastatic breast cancer using endocrine therapy or chemotherapy are infrequent. Breast tumors are known to be heterogeneous with respect to estrogen receptor status, and the low complete remission rate may be related to this biochemical heterogeneity. Based on laboratory experiments using human breast cancer cells in tissue culture, a phase II protocol was designed using tamoxifen, premarin, methotrexate, and 5-fluorouracil. Thus far, twenty-nine (29) patients have been entered into this study and twenty-five (25) are currently evaluable for response. Overall response rate was 72%, and 14 of 25 (56%) attained a complete remission. Toxicity was minimal. Median nadir white blood cell count was 5,800 and median nadir platelet count was 252,000. In summary, this combination chemo-hormonal therapy regimen is effective with a more than 50% complete remission rate and minimal toxicity. More... »

PAGES

93-99

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf01805721

DOI

http://dx.doi.org/10.1007/bf01805721

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1046683463

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/6293630


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adenocarcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Evaluation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Estrogens, Conjugated (USP)", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorouracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Methotrexate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Estrogen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tamoxifen", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Louisville", 
          "id": "https://www.grid.ac/institutes/grid.266623.5", 
          "name": [
            "Division of Medical Oncology, Department of Medicine, University of Louisville, Louisville, Kentucky, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Allegra", 
        "givenName": "Joseph C.", 
        "id": "sg:person.01112043665.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112043665.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Louisville", 
          "id": "https://www.grid.ac/institutes/grid.266623.5", 
          "name": [
            "Division of Medical Oncology, Department of Medicine, University of Louisville, Louisville, Kentucky, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Woodcock", 
        "givenName": "Thomas M.", 
        "id": "sg:person.0661366665.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0661366665.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Louisville", 
          "id": "https://www.grid.ac/institutes/grid.266623.5", 
          "name": [
            "Division of Medical Oncology, Department of Medicine, University of Louisville, Louisville, Kentucky, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Richman", 
        "givenName": "Stephen P.", 
        "id": "sg:person.0613253465.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0613253465.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Louisville", 
          "id": "https://www.grid.ac/institutes/grid.266623.5", 
          "name": [
            "Department of Surgery, University of Louisville, Louisville, Kentucky, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bland", 
        "givenName": "Kirby I.", 
        "id": "sg:person.01310402724.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310402724.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Louisville", 
          "id": "https://www.grid.ac/institutes/grid.266623.5", 
          "name": [
            "Department of Biochemistry, University of Louisville, Louisville, Kentucky, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wittliff", 
        "givenName": "James L.", 
        "id": "sg:person.055356332.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.055356332.16"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1002/1097-0142(197508)36:2+<638::aid-cncr2820360805>3.0.co;2-s", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010993764"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jso.2930090509", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019634024"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(197706)39:6<2934::aid-cncr2820390680>3.0.co;2-p", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022702791"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm197812142992403", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024442011"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(19810601)47:11<2552::aid-cncr2820471106>3.0.co;2-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026754802"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0014-2964(80)90206-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026853325"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.75.2.980", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028177544"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm197806012982203", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029504560"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(197711)40:5<2290::aid-cncr2820400541>3.0.co;2-t", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030818360"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0014-2964(80)90348-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043667003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-88-1-69", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073735321"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074250300", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079517496", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1080482003", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081608880", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1984.2.1.28", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1081678326"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081900341", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082313081", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082748058", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083118733", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1982-03", 
    "datePublishedReg": "1982-03-01", 
    "description": "Complete remissions in patients with metastatic breast cancer using endocrine therapy or chemotherapy are infrequent. Breast tumors are known to be heterogeneous with respect to estrogen receptor status, and the low complete remission rate may be related to this biochemical heterogeneity. Based on laboratory experiments using human breast cancer cells in tissue culture, a phase II protocol was designed using tamoxifen, premarin, methotrexate, and 5-fluorouracil. Thus far, twenty-nine (29) patients have been entered into this study and twenty-five (25) are currently evaluable for response. Overall response rate was 72%, and 14 of 25 (56%) attained a complete remission. Toxicity was minimal. Median nadir white blood cell count was 5,800 and median nadir platelet count was 252,000. In summary, this combination chemo-hormonal therapy regimen is effective with a more than 50% complete remission rate and minimal toxicity.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf01805721", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1092777", 
        "issn": [
          "0167-6806", 
          "1573-7217"
        ], 
        "name": "Breast Cancer Research and Treatment", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "2"
      }
    ], 
    "name": "A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer", 
    "pagination": "93-99", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "de61985d155bb859bffefbe4cf3db2870439306539c7891e7f640a32b06a63dd"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "6293630"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8111104"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf01805721"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1046683463"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf01805721", 
      "https://app.dimensions.ai/details/publication/pub.1046683463"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:34", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000349_0000000349/records_113664_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/BF01805721"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf01805721'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf01805721'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf01805721'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf01805721'


 

This table displays all metadata directly associated to this object as RDF triples.

211 TRIPLES      21 PREDICATES      64 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf01805721 schema:about N12efa368058347f4ba92d2ae12457ae4
2 N31f8b0efbcc24f35b419393acc789dd8
3 N36e622fec8254f4087c018d9bed2130a
4 N3de49498d70c4eb48a98abb4e8f7055a
5 N4f7b3fca44b04df3aaaabdb3886d2ff3
6 N6643e22de1c4438d98441d8d1f0fcf39
7 N734db118756c41d7aadbfdd4ba0f5404
8 N891e3364f79a4fa18cf89ca1864a6780
9 N8fdbeed0c23a4c7692526d48ef9f4f2d
10 N95ecd4b0079f4116a5c555242d9629cc
11 Na7ad0c0e48ce45cc8a4c2d0c980d0e86
12 Nbf3587a0e2a74ffb8211b693dc505504
13 Nc635c89cbf1549a692d0832c1f60a2db
14 Nf06141fb41ef45dab9fc5215c8092983
15 Nf6d82e95782c4fcf8650dc198097fd32
16 anzsrc-for:11
17 anzsrc-for:1112
18 schema:author Nb949e9aa256742b99a94eb22478d616c
19 schema:citation https://app.dimensions.ai/details/publication/pub.1074250300
20 https://app.dimensions.ai/details/publication/pub.1079517496
21 https://app.dimensions.ai/details/publication/pub.1080482003
22 https://app.dimensions.ai/details/publication/pub.1081608880
23 https://app.dimensions.ai/details/publication/pub.1081900341
24 https://app.dimensions.ai/details/publication/pub.1082313081
25 https://app.dimensions.ai/details/publication/pub.1082748058
26 https://app.dimensions.ai/details/publication/pub.1083118733
27 https://doi.org/10.1002/1097-0142(197508)36:2+<638::aid-cncr2820360805>3.0.co;2-s
28 https://doi.org/10.1002/1097-0142(197706)39:6<2934::aid-cncr2820390680>3.0.co;2-p
29 https://doi.org/10.1002/1097-0142(197711)40:5<2290::aid-cncr2820400541>3.0.co;2-t
30 https://doi.org/10.1002/1097-0142(19810601)47:11<2552::aid-cncr2820471106>3.0.co;2-y
31 https://doi.org/10.1002/jso.2930090509
32 https://doi.org/10.1016/0014-2964(80)90206-6
33 https://doi.org/10.1016/0014-2964(80)90348-5
34 https://doi.org/10.1056/nejm197806012982203
35 https://doi.org/10.1056/nejm197812142992403
36 https://doi.org/10.1073/pnas.75.2.980
37 https://doi.org/10.1200/jco.1984.2.1.28
38 https://doi.org/10.7326/0003-4819-88-1-69
39 schema:datePublished 1982-03
40 schema:datePublishedReg 1982-03-01
41 schema:description Complete remissions in patients with metastatic breast cancer using endocrine therapy or chemotherapy are infrequent. Breast tumors are known to be heterogeneous with respect to estrogen receptor status, and the low complete remission rate may be related to this biochemical heterogeneity. Based on laboratory experiments using human breast cancer cells in tissue culture, a phase II protocol was designed using tamoxifen, premarin, methotrexate, and 5-fluorouracil. Thus far, twenty-nine (29) patients have been entered into this study and twenty-five (25) are currently evaluable for response. Overall response rate was 72%, and 14 of 25 (56%) attained a complete remission. Toxicity was minimal. Median nadir white blood cell count was 5,800 and median nadir platelet count was 252,000. In summary, this combination chemo-hormonal therapy regimen is effective with a more than 50% complete remission rate and minimal toxicity.
42 schema:genre research_article
43 schema:inLanguage en
44 schema:isAccessibleForFree false
45 schema:isPartOf N07eab3b39a1443b39843138e8c8fb80c
46 Nb4c31356e6864a1ea4ca45a3a7adf83e
47 sg:journal.1092777
48 schema:name A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer
49 schema:pagination 93-99
50 schema:productId N443f2143d11747c2a5d0dfd56f248c6e
51 N490417484bad45b8a62b2776d63cb8f4
52 N8f0d633bf41b4e66b2ba921496ea8cb4
53 Nb0fb537ef44743c88782c19ea673eb21
54 Ncc42bafeb654464caee938c6f6317a46
55 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046683463
56 https://doi.org/10.1007/bf01805721
57 schema:sdDatePublished 2019-04-11T10:34
58 schema:sdLicense https://scigraph.springernature.com/explorer/license/
59 schema:sdPublisher N4a2d2f2527874d78a1cc3633bf380ef8
60 schema:url http://link.springer.com/10.1007/BF01805721
61 sgo:license sg:explorer/license/
62 sgo:sdDataset articles
63 rdf:type schema:ScholarlyArticle
64 N06e5cbb86c2c4c9aa6506db2751976ce rdf:first sg:person.0613253465.61
65 rdf:rest N6fa7ec53b68749e2a1e66a85510e9d53
66 N07eab3b39a1443b39843138e8c8fb80c schema:issueNumber 1
67 rdf:type schema:PublicationIssue
68 N0ccf8ebc0ca345e3a18fc60e8a86a794 rdf:first sg:person.055356332.16
69 rdf:rest rdf:nil
70 N12efa368058347f4ba92d2ae12457ae4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Methotrexate
72 rdf:type schema:DefinedTerm
73 N31f8b0efbcc24f35b419393acc789dd8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Adult
75 rdf:type schema:DefinedTerm
76 N36e622fec8254f4087c018d9bed2130a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Female
78 rdf:type schema:DefinedTerm
79 N3de49498d70c4eb48a98abb4e8f7055a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Aged
81 rdf:type schema:DefinedTerm
82 N443f2143d11747c2a5d0dfd56f248c6e schema:name doi
83 schema:value 10.1007/bf01805721
84 rdf:type schema:PropertyValue
85 N490417484bad45b8a62b2776d63cb8f4 schema:name readcube_id
86 schema:value de61985d155bb859bffefbe4cf3db2870439306539c7891e7f640a32b06a63dd
87 rdf:type schema:PropertyValue
88 N4a2d2f2527874d78a1cc3633bf380ef8 schema:name Springer Nature - SN SciGraph project
89 rdf:type schema:Organization
90 N4f7b3fca44b04df3aaaabdb3886d2ff3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Antineoplastic Agents
92 rdf:type schema:DefinedTerm
93 N6643e22de1c4438d98441d8d1f0fcf39 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Estrogens, Conjugated (USP)
95 rdf:type schema:DefinedTerm
96 N6fa7ec53b68749e2a1e66a85510e9d53 rdf:first sg:person.01310402724.66
97 rdf:rest N0ccf8ebc0ca345e3a18fc60e8a86a794
98 N734db118756c41d7aadbfdd4ba0f5404 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Receptors, Estrogen
100 rdf:type schema:DefinedTerm
101 N842f60fc5ba24a2d98fc4e5a708e028f rdf:first sg:person.0661366665.98
102 rdf:rest N06e5cbb86c2c4c9aa6506db2751976ce
103 N891e3364f79a4fa18cf89ca1864a6780 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Adenocarcinoma
105 rdf:type schema:DefinedTerm
106 N8f0d633bf41b4e66b2ba921496ea8cb4 schema:name nlm_unique_id
107 schema:value 8111104
108 rdf:type schema:PropertyValue
109 N8fdbeed0c23a4c7692526d48ef9f4f2d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Tamoxifen
111 rdf:type schema:DefinedTerm
112 N95ecd4b0079f4116a5c555242d9629cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Humans
114 rdf:type schema:DefinedTerm
115 Na7ad0c0e48ce45cc8a4c2d0c980d0e86 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Breast Neoplasms
117 rdf:type schema:DefinedTerm
118 Nb0fb537ef44743c88782c19ea673eb21 schema:name pubmed_id
119 schema:value 6293630
120 rdf:type schema:PropertyValue
121 Nb4c31356e6864a1ea4ca45a3a7adf83e schema:volumeNumber 2
122 rdf:type schema:PublicationVolume
123 Nb949e9aa256742b99a94eb22478d616c rdf:first sg:person.01112043665.26
124 rdf:rest N842f60fc5ba24a2d98fc4e5a708e028f
125 Nbf3587a0e2a74ffb8211b693dc505504 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Drug Evaluation
127 rdf:type schema:DefinedTerm
128 Nc635c89cbf1549a692d0832c1f60a2db schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Middle Aged
130 rdf:type schema:DefinedTerm
131 Ncc42bafeb654464caee938c6f6317a46 schema:name dimensions_id
132 schema:value pub.1046683463
133 rdf:type schema:PropertyValue
134 Nf06141fb41ef45dab9fc5215c8092983 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Drug Therapy, Combination
136 rdf:type schema:DefinedTerm
137 Nf6d82e95782c4fcf8650dc198097fd32 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Fluorouracil
139 rdf:type schema:DefinedTerm
140 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
141 schema:name Medical and Health Sciences
142 rdf:type schema:DefinedTerm
143 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
144 schema:name Oncology and Carcinogenesis
145 rdf:type schema:DefinedTerm
146 sg:journal.1092777 schema:issn 0167-6806
147 1573-7217
148 schema:name Breast Cancer Research and Treatment
149 rdf:type schema:Periodical
150 sg:person.01112043665.26 schema:affiliation https://www.grid.ac/institutes/grid.266623.5
151 schema:familyName Allegra
152 schema:givenName Joseph C.
153 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112043665.26
154 rdf:type schema:Person
155 sg:person.01310402724.66 schema:affiliation https://www.grid.ac/institutes/grid.266623.5
156 schema:familyName Bland
157 schema:givenName Kirby I.
158 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310402724.66
159 rdf:type schema:Person
160 sg:person.055356332.16 schema:affiliation https://www.grid.ac/institutes/grid.266623.5
161 schema:familyName Wittliff
162 schema:givenName James L.
163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.055356332.16
164 rdf:type schema:Person
165 sg:person.0613253465.61 schema:affiliation https://www.grid.ac/institutes/grid.266623.5
166 schema:familyName Richman
167 schema:givenName Stephen P.
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0613253465.61
169 rdf:type schema:Person
170 sg:person.0661366665.98 schema:affiliation https://www.grid.ac/institutes/grid.266623.5
171 schema:familyName Woodcock
172 schema:givenName Thomas M.
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0661366665.98
174 rdf:type schema:Person
175 https://app.dimensions.ai/details/publication/pub.1074250300 schema:CreativeWork
176 https://app.dimensions.ai/details/publication/pub.1079517496 schema:CreativeWork
177 https://app.dimensions.ai/details/publication/pub.1080482003 schema:CreativeWork
178 https://app.dimensions.ai/details/publication/pub.1081608880 schema:CreativeWork
179 https://app.dimensions.ai/details/publication/pub.1081900341 schema:CreativeWork
180 https://app.dimensions.ai/details/publication/pub.1082313081 schema:CreativeWork
181 https://app.dimensions.ai/details/publication/pub.1082748058 schema:CreativeWork
182 https://app.dimensions.ai/details/publication/pub.1083118733 schema:CreativeWork
183 https://doi.org/10.1002/1097-0142(197508)36:2+<638::aid-cncr2820360805>3.0.co;2-s schema:sameAs https://app.dimensions.ai/details/publication/pub.1010993764
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1002/1097-0142(197706)39:6<2934::aid-cncr2820390680>3.0.co;2-p schema:sameAs https://app.dimensions.ai/details/publication/pub.1022702791
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1002/1097-0142(197711)40:5<2290::aid-cncr2820400541>3.0.co;2-t schema:sameAs https://app.dimensions.ai/details/publication/pub.1030818360
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1002/1097-0142(19810601)47:11<2552::aid-cncr2820471106>3.0.co;2-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1026754802
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1002/jso.2930090509 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019634024
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1016/0014-2964(80)90206-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026853325
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1016/0014-2964(80)90348-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043667003
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1056/nejm197806012982203 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029504560
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1056/nejm197812142992403 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024442011
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1073/pnas.75.2.980 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028177544
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1200/jco.1984.2.1.28 schema:sameAs https://app.dimensions.ai/details/publication/pub.1081678326
204 rdf:type schema:CreativeWork
205 https://doi.org/10.7326/0003-4819-88-1-69 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073735321
206 rdf:type schema:CreativeWork
207 https://www.grid.ac/institutes/grid.266623.5 schema:alternateName University of Louisville
208 schema:name Department of Biochemistry, University of Louisville, Louisville, Kentucky, USA
209 Department of Surgery, University of Louisville, Louisville, Kentucky, USA
210 Division of Medical Oncology, Department of Medicine, University of Louisville, Louisville, Kentucky, USA
211 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...